GT Biopharma Inc
NASDAQ:GTBP
GT Biopharma Inc
Cash from Investing Activities
GT Biopharma Inc
Cash from Investing Activities Peer Comparison
Competitive Cash from Investing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
GT Biopharma Inc
NASDAQ:GTBP
|
Cash from Investing Activities
-$2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-119%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Investing Activities
-$2B
|
CAGR 3-Years
62%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Investing Activities
-$2.3B
|
CAGR 3-Years
48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-76%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Investing Activities
-$27.8B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Investing Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-73%
|
CAGR 10-Years
-50%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Investing Activities
-$4.6B
|
CAGR 3-Years
-89%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-26%
|
See Also
What is GT Biopharma Inc's Cash from Investing Activities?
Cash from Investing Activities
-2m
USD
Based on the financial report for Dec 31, 2023, GT Biopharma Inc's Cash from Investing Activities amounts to -2m USD.
What is GT Biopharma Inc's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 5Y
-119%